This combination nasal spray is commonly used to help with the symptomatic treatment of moderate to severe allergic rhinitis (hay fever) and associated eye symptoms.

Comprehensive Relief from Bothersome Allergy Symptoms

This medication is generally used to help with a wide range of distressing symptoms of seasonal and perennial allergic rhinitis, such as a runny nose, sneezing, nasal itching, and congestion. It provides support that helps ease the overall symptom burden, contributing to easier breathing and general comfort.

Targeting Combined Nasal and Eye Discomfort

The treatment is applied across domains where additional symptomatic support is needed, specifically for managing symptoms that interfere with daily comfort, including both nasal issues and associated eye irritation (watering, itching, and redness). This assists with general functional comfort during periods when multiple symptoms become more noticeable.

Managing Moderate to Severe Symptom Intensity

Dymista is relevant for easing challenging symptomatic manifestations, often used in conditions characterized by periods of heightened symptoms when single-ingredient treatments have not provided sufficient relief. This supportive relief may help patients cope more steadily with symptom fluctuations and supports general comfort during symptomatic phases.

Quick Fact: Relief for Combination Symptoms The medication is relevant when symptoms cluster together, providing supportive relief for both key nasal symptoms and related eye irritation.

The regulatory eligibility profile for Dymista 125/50 defines the specific patient groups who can and cannot use the medicine. Absolute prohibition is established for patients with a known hypersensitivity to azelastine hydrochloride, fluticasone propionate, or any component of the nasal spray formulation.

The medicine is officially approved for use in adults and adolescents, with the minimum approved age being 6 years and older in countries like the US and Australia. However, it is not recommended for children below this age threshold, as safety and efficacy are not established. For adolescents receiving prolonged treatment, regulators advise routine growth monitoring.

Use is restricted or conditional in several patient groups. Due to the inhibitory effect on wound healing, treatment must be avoided in patients with recent nasal surgery, trauma, or ulcers until healing has occurred. Caution is also advised for patients with severe liver disease and those with a history of glaucoma or cataracts, which require close monitoring. In cases of untreated respiratory tract infections or tuberculosis, the potential benefit of use must be carefully weighed against possible risks. For pregnancy and lactation, use is permitted only if the regulatory-defined benefit to the mother outweighs the potential risk to the child.

Interactions with other medicines and products

Dymista 125/50 contains two active components, azelastine hydrochloride and fluticasone propionate, and interactions relate to the properties of both.

Pharmacokinetic Interactions

Co-treatment with potent inhibitors of Cytochrome P450 (CYP) 3A4 is expected to increase the systemic exposure to fluticasone propionate. This increase raises the risk of systemic corticosteroid side effects, such as hypercorticism and adrenal suppression. Medicines in this class include ritonavir and ketoconazole, among others.

• Ritonavir: Coadministration is generally not recommended or should be avoided unless the potential benefit significantly outweighs the increased risk, requiring close monitoring for systemic corticosteroid effects.
• Other Potent CYP3A4 Inhibitors (e.g., Ketoconazole, Cobicistat-containing products): Caution is advised with co-treatment, and monitoring is necessary.

Pharmacodynamic Interactions

Interactions involving the azelastine component relate to additive central nervous system (CNS) effects:

• Alcohol and other CNS depressants (e.g., certain sedatives or tranquilizers): Concurrent use should be avoided as it may cause additive reductions in alertness and further impairment of CNS performance.

Other Considerations

The use of Dymista 125/50 concomitantly with other inhaled or intranasal corticosteroids may increase the total systemic corticosteroid load, potentially increasing the risk of systemic effects.

Dymista 125/50 operates through the complementary actions of its two components: azelastine hydrochloride and fluticasone propionate. Azelastine functions as a selective H1-receptor antagonist. It competes with endogenous histamine for binding sites on the H1 receptors, thereby preventing the initiation of the immediate allergic cascade. Azelastine also acts to stabilize mast cells, which leads to the subsequent inhibition of the release of inflammatory mediators, including histamine and leukotrienes. Fluticasone propionate is a synthetic glucocorticoid that acts as an agonist of the cytosolic Glucocorticoid Receptor (GR). Upon ligand binding, the activated Fluticasone-GR complex translocates into the cell nucleus, where it modulates gene transcription. This process involves transrepression, which inhibits the expression of pro-inflammatory proteins such as cytokines, chemokines, and COX-2. It also includes transactivation, which increases the synthesis of anti-inflammatory proteins. This nuclear modulation ultimately prevents the local recruitment of inflammatory cells, leading to system-level physiological suppression of both the early and late phases of the inflammatory response.

The administration of Dymista 125/50 involves specific requirements regarding the route, frequency, and preparation of the medicine. The dual-component drug is formulated as a metered-spray suspension and is intended exclusively for intranasal use. The standard dosing regimen for both adults and children aged 6 years and older is one spray into each nostril, twice daily, typically administered in the morning and the evening.

Administration Logistics

Dosing Duration and Adjustments

Use of the medicine should align with the period of allergenic exposure. Once initial symptom control is established, the dose should be reduced to the lowest effective level that maintains the therapeutic effect. Furthermore, no dose adjustment is typically required for older adults (elderly patients) or individuals with renal or mild to moderate hepatic impairment.

Research evidence / Overview of studies for Dymista 125/50

Evidence for Use in Moderate to Severe Allergic Rhinitis in Adults and Adolescents

Research has explored how symptoms change over time for the combination of Azelastine and Fluticasone propionate in Randomized Controlled Trials (RCTs). These short-term studies often tracked outcomes over 2 to 4 weeks, conducted during periods of increased symptom activity. These trials included adults and adolescents 12 years of age and older who had been diagnosed with allergic rhinitis, a condition characterized by fluctuating or episodic manifestations.

In these studies, research examined outcomes related to physical discomfort, specifically using the Reflective Total Nasal Symptom Score (rTNSS). This score is relevant in evidence describing how symptoms are measured, tracking issues like sneezing, runny nose, and congestion. Studies also explored patient-reported outcomes describing perceived discomfort related to eye symptoms and functional outcomes reflecting daily functioning or activity level. The main comparative measurement data is derived from these short-term treatment periods. Research does not provide individual predictions about how an individual will respond, as study results reflect the specific conditions and populations under which they were conducted.

Evidence for Use in Younger Children (6 to 11 years)

Research has explored the combination in a specific pediatric population through short-term, placebo-controlled clinical trials designed for children aged 6 to 11 years experiencing seasonal allergic rhinitis. The evidence base for this age group included a different set of studies compared to adults, focusing on outcomes related to the children's rTNSS scores. However, the evidence is still developing, and data for certain groups, such as children younger than 6, remain insufficient.

Long-Term Research and Follow-up Duration

Clinical research has explored the long-term observation of the medicine through dedicated extended studies, which monitored data for up to 52 weeks (one year). Research exploring long-term symptom patterns over a continuous one-year period is less characterized than the short-term findings. Information regarding long-term outcomes and the durability of the observed changes is limited.

What Research Gaps and Uncertainties Remain

A key limitation is that follow-up durations for comparative measurement studies were often limited to 2 to 4 weeks, meaning long-term outcomes are not fully established. Furthermore, specific research is lacking for the pediatric group. Studies examining the potential long-term effects on the Hypothalamic-Pituitary-Adrenal (HPA) axis or the growth rate of children have not been conducted. This reflects a limitation regarding the absence of specific long-term studies for this combination.

Common questions about Dymista 125/50 (FAQ)

Q: What specific type of nasal condition is Dymista officially approved to treat?

According to official product information, this medicine is indicated for the relief of symptoms related to seasonal allergic rhinitis (commonly known as hay fever) in patients 6 years of age and older. In some regions, its use may also include symptoms of allergic rhino-conjunctivitis.

Q: What is the meaning of the numbers 125 mcg and 50 mcg in the drug name Dymista 125/50?

The numbers refer to the amount of each active ingredient delivered in a single actuation of the spray. Regulatory documents state that each spray provides 125 mcg of azelastine and 50 mcg of fluticasone propionate.

Q: Is drowsiness a side effect related to the azelastine component or the fluticasone component?

Official information indicates that the potential for somnolence (drowsiness) is associated with the azelastine component, which is a type of antihistamine. This is listed in official documents as a known, though often rare, adverse reaction.

Q: Can Dymista potentially cause mood changes, such as anxiety or restlessness?

Some postmarketing reports have noted adverse effects, including mental or mood changes, in association with its use. As the product contains a corticosteroid, systemic absorption may rarely be linked to such effects.

Q: What are the signs of potential thrush (Candida infection) in the nose or throat from Dymista use?

The use of intranasal corticosteroids carries a documented risk of localized infections with Candida albicans (thrush). This type of infection typically appears as white patches inside the nose or throat, as noted in official safety information.

Q: Does Dymista carry any warnings related to bone density or osteoporosis with prolonged use?

Official product information indicates that the systemic effects of intranasal steroids may include a reduction of bone density. This potential risk is generally associated with using higher doses over prolonged periods of time.

Q: Can Dymista cause a change in heart rhythm or palpitations?

Postmarketing surveillance reports have included adverse reactions such as palpitations (a noticeable, rapid, or irregular heartbeat) and atrial fibrillation. This information is recorded in official regulatory documents.

Q: What precautions are listed regarding driving or operating machinery while using Dymista?

Due to the potential for somnolence (drowsiness), official guidance notes that engaging in hazardous occupations requiring complete mental alertness, such as driving or operating machinery, may carry a risk.

Q: How quickly does Dymista start to relieve allergy symptoms after the first use?

Clinical study data indicates that relief of nasal symptoms has been observed to begin as early as 5 minutes following administration. However, the full anti-inflammatory effect provided by the steroid component may take several days to fully develop.

Q: Is Dymista a medication that provides immediate relief or does it require continuous daily use?

The medicine contains an antihistamine component that may provide rapid symptom relief and a steroid component that requires time for full anti-inflammatory action. The medicine is administered twice daily to maintain a continuous therapeutic effect.

Q: How long is a patient typically expected to use Dymista for maximum benefit?

Regulatory guidelines state that the duration of use is generally intended to cover the period of allergenic exposure. The medicine may be suitable for continuous use up to 6 months, depending on the specific product license.

Q: Does Dymista become less effective over a long period of regular use?

Regulatory documents do not specifically state a definite loss of effect. However, they note that long-term observation studies (up to one year) have provided limited information regarding the durability of observed symptom relief over an extended period.

Q: What is the typical duration of allergy relief expected after one dose of Dymista?

The recommended dosing schedule involves administration twice daily (morning and evening). This dosing schedule is intended to support a continuous therapeutic effect over a 24-hour period.

Q: Can a user feel the spray liquid going down the back of the throat if administered correctly?

Unpleasant taste (dysgeusia) is a common side effect often resulting from the medicine running down the throat. To help limit this, administration instructions guide the user to tilt the head slightly forward or downward while spraying.

Q: Are there any long-term effects associated with the non-steroidal component (azelastine) in the nasal spray?

Most long-term warnings relate to the corticosteroid component. However, the azelastine component has been associated with postmarketing reports of long-term effects such as a change or loss of sense of smell and/or taste.

Q: What is the official classification or guidance regarding the use of Dymista during pregnancy?

Official labeling states there are no adequate and well-controlled studies of the medicine in pregnant women. The decision to use this medicine during pregnancy is based on a healthcare provider's assessment of whether the potential benefit justifies the potential risk to the fetus.

Q: What are the considerations for using Dymista while breastfeeding?

It is unknown whether the active components of the medicine are excreted into human breast milk. Official documents state that caution is necessary when the medicine is administered to a nursing woman, and a clinician must weigh the potential benefits against the risks.

Q: Why is Dymista contraindicated for patients with recent nasal surgery, injury, or sores?

Official warnings state that the medicine should be avoided until healing has occurred after recent nasal ulcers, surgery, or trauma. This is because corticosteroids can have an inhibitory effect on wound healing.

Q: What is the concern about using Dymista when a person has an existing infection like tuberculosis or ocular herpes?

Regulatory warnings advise that corticosteroids should be used with caution in patients with certain systemic infections, including tuberculous, fungal, or viral infections (e.g., ocular herpes simplex). This is due to the potential for corticosteroids to compromise a person's response to certain existing infections.

Q: Why is the specific tilt of the head important when administering the spray?

Administration instructions guide the patient to tilt the head slightly downward or forward while spraying. This specific technique is recommended to help ensure the medicine is properly delivered and to limit the amount of spray that runs to the back of the throat.

Q: Is it better to gently sniff or sniff hard when using the nasal spray applicator?

Inhaling gently inward is noted in administration instructions to help ensure the medicine is properly directed and avoid the spray traveling directly to the back of the throat. Sniffing too hard can cause the medicine to bypass the intended nasal areas.

Q: Does Dymista treat both seasonal and perennial allergic rhinitis?

The product is officially indicated for the relief of symptoms of seasonal allergic rhinitis. While the individual components have been referenced for use in perennial rhinitis, the combination product is primarily indicated for seasonal allergic rhinitis.

Q: Can Dymista be used for conditions other than allergies, such as non-allergic rhinitis?

The medicine is officially indicated for the relief of symptoms of allergic rhinitis; it is not indicated for non-allergic conditions like the common cold or other forms of rhinitis.

Q: Is Dymista available as a generic medicine, or only as the brand name?

The product is available in brand name form. Regulatory information indicates that there is also an FDA-approved Authorized Generic version available.

Q: What is the purpose of the excipient benzalkonium chloride in the Dymista formulation?

The excipient benzalkonium chloride serves as a preservative in the formulation. Official warnings mention this ingredient because it may cause irritation inside the nose, especially when the medicine is used for a long period of time.

Q: Is it normal to feel a blockage or increased congestion after the first few uses of Dymista?

Although the medicine is intended to relieve congestion, official documents list side effects that may include nasal congestion or rhinitis. If a user experiences this, it is considered an adverse reaction.

Q: Why must Dymista be stored in its original container and away from light?

Regulatory documents specify that the product is a light-sensitive aqueous suspension. Storing it in the original container helps protect it from light exposure, which is necessary to maintain the medicine's stability and integrity.

Q: Are there any warnings regarding potential impaired wound healing while using Dymista?

Yes, corticosteroids have an inhibitory effect on wound healing. Due to this, official warnings state that patients with recent nasal injury or surgery should postpone using the medicine until the healing process is complete.

Q: Can Dymista cause a feeling of fullness or pressure in the ears?

Official adverse event summaries list ear congestion as a less common side effect. This may be experienced as a feeling of fullness or pressure in the ears.

Q: Can Dymista be used to treat symptoms of a common cold?

The medicine is officially indicated for the relief of symptoms of allergic rhinitis. It is not indicated for the common cold.

Storage Requirements

Official regulatory documents define strict conditions for storing Dymista 125/50 nasal spray to maintain its stability. The product must be stored at controlled room temperature, specifically below 25 C (77 F).

Disposal Instructions

When the medicine is no longer needed or has passed its discard date, it must be handled according to authorized pharmaceutical waste procedures. The official instruction for disposal is to ask a pharmacist what to do with any leftover or expired medicine.